Hi, today we are going to talk about Immunogen and its current landscape.

Immunogen is poised to receive increasing attention from the market after the announcement that it will start new trials based on an FDA advice that a new single-arm study in ovarian cancer could support accelerated approval for Mirvetuximab Soravtansine. We must remember that statistics show that in 2019, about 22,530 women* were expected to be diagnosticated with ovarian cancer, and is expected a mortality of 13,980 women in the same period, which shows the potential growth of this product once hit the market (after the FDA approval), depending on the outcome Immunogen can back to see shining days once more.

Thank you for reading and leave your comments if you like.

To have access to our exclusive contents, join the Traders Heaven today! Link Below.

Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.

*Source: American Cancer Society
Nosso canal no Telegram:


Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Referred friends Coins My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out